Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s
Moderna’s COVID-19 vaccine looks better than Pfizer/BioNTech’s at preventing severe disease and like it may offer some benefit in preventing asymptomatic infections, but these advantages may be short-lived and hard to capitalize on due to supply limitations.
